A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.

Trial Profile

A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Xiamen Amoytop Biotech
  • Most Recent Events

    • 28 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 29 Nov 2013 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top